AR028002A1 - Metodos para la produccion de ansamitocina - Google Patents

Metodos para la produccion de ansamitocina

Info

Publication number
AR028002A1
AR028002A1 ARP010101696A ARP010101696A AR028002A1 AR 028002 A1 AR028002 A1 AR 028002A1 AR P010101696 A ARP010101696 A AR P010101696A AR P010101696 A ARP010101696 A AR P010101696A AR 028002 A1 AR028002 A1 AR 028002A1
Authority
AR
Argentina
Prior art keywords
ansamitocine
production
methods
ansamitocine production
Prior art date
Application number
ARP010101696A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR028002A1 publication Critical patent/AR028002A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP010101696A 2000-04-12 2001-04-10 Metodos para la produccion de ansamitocina AR028002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19636100P 2000-04-12 2000-04-12

Publications (1)

Publication Number Publication Date
AR028002A1 true AR028002A1 (es) 2003-04-23

Family

ID=22725075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101696A AR028002A1 (es) 2000-04-12 2001-04-10 Metodos para la produccion de ansamitocina

Country Status (21)

Country Link
US (2) US6573074B2 (es)
EP (1) EP1272653B1 (es)
JP (1) JP4832697B2 (es)
KR (1) KR20030036159A (es)
CN (1) CN1432068A (es)
AR (1) AR028002A1 (es)
AT (1) ATE331804T1 (es)
AU (2) AU9333501A (es)
BR (1) BR0109975A (es)
CA (1) CA2406188A1 (es)
CZ (1) CZ20023356A3 (es)
DE (1) DE60121150T2 (es)
ES (1) ES2266243T3 (es)
HU (1) HUP0300473A3 (es)
IL (1) IL152241A0 (es)
MX (1) MXPA02010109A (es)
NO (1) NO20024893D0 (es)
NZ (1) NZ521868A (es)
PL (1) PL365577A1 (es)
WO (1) WO2001077360A2 (es)
ZA (1) ZA200208159B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AR030612A1 (es) * 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US6790954B2 (en) * 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
AU2003257210A1 (en) * 2002-08-08 2004-02-25 Smithkline Beecham Corporation Methods for the isolation and purification of ansamitocins
WO2005020883A2 (en) * 2003-05-08 2005-03-10 Immunogen, Inc. Methods for the production of ansamitocins
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US20070135629A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Isolation of ansamitocins
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
CN100420754C (zh) * 2006-10-26 2008-09-24 浙江海正药业股份有限公司 一种制备蒽莎姆菌素的方法
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
CN102505023A (zh) * 2011-11-18 2012-06-20 华东理工大学 一种dahp合酶的异源可溶性表达方法及其重组载体和基因工程菌
CN108276427A (zh) * 2018-01-14 2018-07-13 常州大学 一种安丝菌素p-3的提取与分离纯化方法
CN110117626A (zh) * 2018-02-06 2019-08-13 上海键合医药科技有限公司 一种制备安丝菌素p3的发酵工艺
PL3956332T3 (pl) 2019-04-18 2023-05-29 Indena S.P.A. Diastereoselektywny sposób wytwarzania estrów majtanzynoidowych zawierających tiol lub dwusiarczek i ich produkty pośrednie
CN113444106A (zh) * 2020-03-25 2021-09-28 重庆乾泰生物医药有限公司 一种高纯度安丝菌素的制备方法
WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2022262591A1 (zh) * 2021-06-18 2022-12-22 杭州中美华东制药有限公司 安丝菌素p-3的提纯方法
WO2023057893A1 (en) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1314019A (en) * 1969-07-19 1973-04-18 Rolland Sa A Antibiotic substance and process for the extraction of such an antibiotic substance from a strain of pseudomonas
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4162940A (en) 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
JPS6010718B2 (ja) 1977-03-31 1985-03-19 武田薬品工業株式会社 メイタンシノ−ル,メイタナシンおよびメイタンシノ−ル・プロピオネ−トの製造法
JPS6016236B2 (ja) 1977-11-18 1985-04-24 武田薬品工業株式会社 抗生物質c―15003 p―3の製造法
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS56102793A (en) 1979-12-28 1981-08-17 Takeda Chem Ind Ltd Preparation of antibiotic c-15003 p-3
US4423211A (en) * 1981-12-21 1983-12-27 Merck & Co., Inc. Process for the whole broth extraction of avermectin
JPH0347090A (ja) * 1988-12-27 1991-02-28 Takeda Chem Ind Ltd 二重特異性を有するハイブリッドモノクローナル抗体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2069439A1 (en) 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
FR2656874B1 (fr) * 1990-01-11 1992-04-03 Commissariat Energie Atomique Procede de production et d'extraction d'anti-oxydants a partir d'une culture de micro-organismes et photobioreacteur pour la mise en óoeuvre de ce procede.
DE4037441A1 (de) * 1990-11-24 1992-05-27 Basf Ag Verfahren zur erhoehung des riboflavin-gahaltes in spruehgetrockneten fermenteraustraegen bei riboflavin-fermentationen
JPH08214870A (ja) * 1995-02-17 1996-08-27 Kanegafuchi Chem Ind Co Ltd ファフィア・ロドチーマ酵母の細胞壁処理方法
CN1056845C (zh) * 1995-03-03 2000-09-27 弗·哈夫曼-拉罗切有限公司 核黄素的纯化

Also Published As

Publication number Publication date
NO20024893L (no) 2002-10-10
DE60121150D1 (de) 2006-08-10
US6573074B2 (en) 2003-06-03
EP1272653A2 (en) 2003-01-08
CZ20023356A3 (cs) 2003-04-16
WO2001077360A3 (en) 2002-09-12
CN1432068A (zh) 2003-07-23
KR20030036159A (ko) 2003-05-09
PL365577A1 (en) 2005-01-10
AU2001293335B2 (en) 2005-02-24
US20020015984A1 (en) 2002-02-07
NO20024893D0 (no) 2002-10-10
BR0109975A (pt) 2004-03-23
JP4832697B2 (ja) 2011-12-07
ES2266243T3 (es) 2007-03-01
WO2001077360A2 (en) 2001-10-18
DE60121150T2 (de) 2007-05-16
HUP0300473A3 (en) 2004-07-28
MXPA02010109A (es) 2003-02-12
HUP0300473A2 (hu) 2003-06-28
ZA200208159B (en) 2003-10-17
JP2003530114A (ja) 2003-10-14
IL152241A0 (en) 2003-05-29
US20030157669A1 (en) 2003-08-21
ATE331804T1 (de) 2006-07-15
EP1272653B1 (en) 2006-06-28
CA2406188A1 (en) 2001-10-18
AU9333501A (en) 2001-10-23
NZ521868A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
DE60205413D1 (de) Herstellungsverfahren
AR027956A1 (es) Nuevas combinaciones de farmacos
DE50115520D1 (de) Strahlformungsverfahren
DE60134167D1 (de) Stanze
AR028002A1 (es) Metodos para la produccion de ansamitocina
DE10196082T1 (de) FLIP-CHIP-Montageverfahren
AR028201A1 (es) Metodo para aliviar la ansiedad
IS6716A (is) Aðferðir við að framleiða sílostasól
DE50100418D1 (de) Brezelherstellungssystem
DE60115364D1 (de) Herstellungsverfahren für stranggussknüppel
AR028078A1 (es) Proceso para la produccion de grrnulos de enzimas
DE50101454D1 (de) Fertigungsstrassenabschnitt
PT1259535E (pt) Derivados de hexapeptideo ciclico
DE60130426D1 (de) Aluminiumoxid-Leuchtstoff- Herstellungsverfahren
AR027987A1 (es) Un metodo para la preparacion de ciclopropenos
AR028550A1 (es) Procedimiento para la obtencion de caprolactama
AR028328A1 (es) Proceso para la preparacion de heterociclos benzo-fusionados
AR028111A1 (es) Procedimiento para la produccion de isocianatos
DE60012372D1 (de) Verbesserte herstellungsmethode für acylferrocene
PT9699T (pt) Dispositivo retrovisor para ciclistas
ES1046497Y (es) Escurridor para mochos
ID29728A (id) Proses untuk pembuatan piridin-piridin tersubstitusi
NO20025598L (no) Roterende dör
ES1046576Y (es) Bovedilla para forjados
AR028548A1 (es) Procedimiento para la obtencion de caprolactama

Legal Events

Date Code Title Description
FB Suspension of granting procedure